Vitamin-based therapy for Metastatic tumors: 1,25-dihydroxyvitamin D decreases the expression of PD-1, a suppressor of activation of T-cells, and activates the immune system via down regulation of its target gene, 8/March/2015, 22.28

Interleukin-based anti-cancer therapy: Interleukin-37 (IL-37) increases the expression of BTG2 via down regulation of its target gene, 08/March/2015, 17.13
March 8, 2015
Molecular therapy for pulmonary hypertension: MiRNA-222 suppresses pulmonary hypertension via down regulation of its target gene, 08/March/2015, 22.31
March 8, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, L., Vitamin-based therapy for Metastatic tumors: 1,25-dihydroxyvitamin D decreases the expression of PD-1, a suppressor of activation of T-cells, and activates the immune system via down regulation of its target gene, 8/March/2015, 22.28, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: 

It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year. 

The study presented here suggests that 1,25-dihydroxyvitamin D, by decreasing the expression of its target gene, it may suppress the expression of PD-1.  Thereby, it may activate the immune system and inhibit metastatic progression. Thus, pharmacological formulations encompassing “1,25-dihydroxyvitamin D  or its analogues may be used to inhibit the progression of tumors.

Undisclosed information: How  “1,25-dihydroxyvitamin D suppresses the expression of PD-1

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.